Join us at the Cell & Gene Meeting on the Mesa in Phoenix from October 7-9 and meet The Dedham Group’s Jennifer (Goldenberg) Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, and Kathryn Moses, Principal, Director of Cell and Gene Therapy Strategy. https://ow.ly/9uSF50TpIOX Jen is a renowned thought leader featured in Cell & Gene, The Medicine Maker, and PharmaVoice, and Katie has been instrumental in The Dedham Group’s research on clinical trials design relevance for commercial launch. Don't miss this opportunity to gain insights into market access strategies. Schedule your meeting today!
The Dedham Group
Business Consulting and Services
New York, NY 17,390 followers
Management and Strategic Consulting Services
About us
The Dedham Group is the premier US oncology & specialty therapeutics strategy consulting firm that combines deep clinical expertise in specialty disease areas, commercial & market access expertise and proprietary analytics to provide highly differentiated recommendations & strategic support to our clients in the pharmaceutical and biotech industry. Our work focuses on being highly data-driven and developing highly custom and integrated strategies in exciting areas of clinical innovation which span oncology, cell & gene therapy, immunology, neurology, rare diseases and precision medicine. We are deeply embedded with our clients which span senior leaders across sales & marketing, market access, distribution & patient services, pricing & contracting and channel strategy across marquee brands on the cutting edge of clinical innovation from many of the most admired companies. Our team is comprised of highly talented entrepreneurial, collaborative and creative leaders that are focused on insights development, storytelling and creating custom strategies & products for our strategic clients, maintaining the high quality & deep specialization expectations of a boutique firm. Our organization prides itself on being a merit-driven, team-based, high-performance culture where our people care greatly about their clients’ careers, the impact of their work and the overall well-being of their colleagues.
- Website
-
http://www.dedhamgroup.com
External link for The Dedham Group
- Industry
- Business Consulting and Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2010
- Specialties
- Consulting, Healthcare, and Research
Locations
-
Primary
1 Penn Plaza
Suite 2505
New York, NY 10119, US
Employees at The Dedham Group
Updates
-
By developing proactive strategies that address both affordability and access issues, manufacturers and life sciences organizations can help patients receive the therapies they need without undue financial burden, writes Rebecca Leemputte. Check out our latest thought leadership article to learn more about navigating IRA-related changes heading into 2025. https://ow.ly/Sq1u50Tpwf9
-
Stay ahead in today’s dynamic landscape with The Dedham Group’s Digital Health & Access Innovation Unit: https://ow.ly/wcIG50T4vf5. With 20 years of expertise, we offer strategic solutions and market insights tailored to the pharmaceutical industry. Drive forward-thinking digital health strategies with us. Click the link in this post to learn more.
-
Join us at the Cell & Gene Meeting on the Mesa in Phoenix, October 7-9! https://ow.ly/Y25m50TlxtN The Dedham Group will be on site to share how we help cell and gene therapy manufacturers excel in commercialization and access strategies. Learn about our tailored services designed to optimize market success. Don’t miss out—schedule your meeting with our experts today!
-
In case you missed it, watch the webinar "Your Proactive IRA Strategy: Navigating Patient Support Program Challenges." https://ow.ly/ca0k50Tulm7 Join Rebecca Lamputte, Associate Partner at The Dedham Group and AssistRx, as she explores strategies for helping patients and healthcare providers navigate the Inflation Reduction Act's impact on access and affordability.
-
In a recent Specialty Pharmacy Continuum article, Jennifer (Goldenberg) Klarer, M.Sc.Eng. of The Dedham Group and Dinesh Kannan Kabaleeswaran of MMIT (Managed Markets Insight & Technology) discuss an industry survey revealing the top concerns of pharma executives and their optimism about upcoming clinical advancements. Read the full article here: https://ow.ly/9oAh50Tpp8C.
-
Heading to the Cell & Gene Meeting on the Mesa in Phoenix from October 7-9? Don’t miss your chance to meet our experts, Jennifer (Goldenberg) Klarer, M.Sc.Eng., Managing Partner and Head of Cell & Gene Therapy, and Kathryn Moses, Principal, Director of Cell and Gene Therapy Strategy. https://ow.ly/9YL250TpIOT Jen’s thought leadership has been featured in Cell & Gene, The Medicine Maker, and PharmaVoice, and Katie was instrumental in TDG’s research on clinical trial design relevance for commercial launch. Discover how we partner with cell and gene therapy manufacturers to develop and commercialize effective access strategies. Book your meeting with us today!
-
As the IRA reshapes the healthcare environment, manufacturers and life sciences organizations have a unique opportunity to be at the forefront of patient support. In our new thought leadership article, Rebecca Leemputte explains the challenges and opportunities heading into 2025. https://ow.ly/NoMl50TpvvE
-
In a recent BioSpace BioSpace article, Manuel Jurado of The Dedham Group examines how the rise of direct-to-consumer strategies is transforming patient access, drug pricing, and pharmaceutical marketing. Read the full article for more insights. https://ow.ly/8wNo50Tluw1
-
Are you attending the Cell & Gene Meeting on the Mesa from October 7-9 in Phoenix, AZ? Don’t miss the chance to connect with experts from The Dedham Group! https://ow.ly/1eru50Tlxor We’ll be onsite discussing how we help cell and gene therapy manufacturers achieve success with commercialization and access strategies. Discover how we elevate payer discussions, simplify provider adoption, and optimize commercial operations for seamless execution. Schedule a meeting with us today!